Skip to main content

Table 2 Comparison of clinicopathological data and survival between the PHC subgroup and PBTC subgroup

From: Prognosis and survival analysis of patients with pancreatic cancer: retrospective experience of a single institution

Characteristics Tumor location P
Head Body/tail
mOS(95%CI) 9.9 (8.7-11.2) 8.4 (6.7-10.1) 0.041***
Age (years) 60.47±9.76 60.94±9.63 0.568*
Sex Male:Female 224:189 115:92 0.798**
Pain on the back and loin No:Yes 334:79 128:79 0.000**
Somking history No:Yes 254:159 139:68 0.098**
Diabetes history No:Yes 233:180 119:88 0.434**
CA199(U/ml) 258.7 (0.5-37192) 195 (0.5-327524) 0.336##
CEA (ng/ml) <5:≥5 272:141 127:80 0.287**
Total bilirubin (umol/l) 97.9 (0.92-1221.8) 10.4 (2.3-405.7) 0.000##
Albumin(g/l) <35:≥35 61:352 15:192 0.006**
NLR <5:≥5 361:52 180:27 0.899**
Peripancreatic invasion No:Yes 194:219 46:161 0.000**
Weight loss (kg) <5:≥5 234:179 123:84 0.547**
Operative procedure Wo:Po:Rr 99:70:244 79:10:118 0.000#
Tumor size (cm) 3.1 (1.0-9.0) 4.4 (1.2-11.2) 0.000##
Lymph node metastasis No:Yes 277:136 141:66 0.856**
Hepatic metastasis No:Yes 370:43 166:41 0.020**
Number of distant organ metastatic 0:1:≥2 339:60:14 119:51:37 0.000#
Adjuvant chemotherapy No:Yes 376:37 188:19 0.518**
  1. P was examined by the #Pearson chi-square test or ##Mann-Whitney U test or *Student’s t-test or **chi-square test (Fisher’s exact test) or ***log-rank test for univariate survival analysis
  2. Numbers in parentheses are the ranges of values
  3. NLR Neutrophil-lymphocyte ratio
  4. Wo Without operation, Po Palliative operation, Rr Radical resection